TY  - JOUR
AU  - Blancas, I
AU  - Fontanillas, M
AU  - Conde, V
AU  - Lao, J
AU  - Martinez, E
AU  - Sotelo, M J
AU  - Jaen, A
AU  - Bayo, J L
AU  - Carabantes, F
AU  - Illarramendi, J J
AU  - Gordon, M M
AU  - Cruz, J
AU  - Garcia-Palomo, A
AU  - Mendiola, C
AU  - Perez-Ruiz, E
AU  - Bofill, J S
AU  - Baena-Cañada, J M
AU  - Jañez, N M
AU  - Esquerdo, G
AU  - Ruiz-Borrego, M
PY  - 2017
DO  - 10.1007/s12094-017-1797-9
UR  - http://hdl.handle.net/10668/13021
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Introduction: This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving antiestrogen therapy in clinical...
LA  - en
PB  - Springer
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Metastatic breast cancer
KW  - Postmenopausal women
KW  - Hormone receptor-positive advanced breast cancer
KW  - Fulvestrant
KW  - Breast Neoplasms
KW  - Ki-67 Antigen
KW  - Progression-Free Survival
KW  - Receptors, Estrogen
KW  - Spain
KW  - Postmenopause
TI  - Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
TY  - research article
VL  - 20
ER  -